Good News! Mabwell's First Drug Adalimumab Approved for Marketing

Release time:Mar 03, 2022

Mabwell (Shanghai) Bioscience Co., Ltd. (hereinafter referred to as "Mabwell", 688062.SH) and Shanghai Junshi Biosciences Co., Ltd. (hereinafter referred to as "Junshi", 1877.HK, 688180.SH) jointly announced that the co-developed adalimumab solution for injection (trade name: 君迈康?, Mabwell project code: 9MW0113, Junshi project code: UBP1211) had been formally approved for marketing by the National Medical Products Administration (NMPA) (S20220008). 君迈康? is used for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriasis, and has received support from the Major Scientific and Technological Special Project for Significant New Drug Development during the Twelfth Five-year Plan Period.

Dr. Liu Datao, the co-founder and CEO of Mabwell, said: "This is the first drug marketed by Mabwell and also an important milestone in Mabwell’s layout of the entire industry chain. Mabwell has established an integrated professional academic promotion and marketing team which puts market leadership, medical drive and market access first and is based in China with a global perspective. We focus on improving the accessibility of domestic markets and exploring extension to fast-growing emerging markets so as to obtain larger market shares. We will continue promoting the R&D and commercialization of more innovative products to further meet the clinical needs of patients worldwide."

Dr. Li Ning, Junshi's CEO, said: "ten years after Junshi was founded, we are quite pleased to see the company's third product successfully enter its commercial phase. There are more than 15 million patients with rheumatoid arthritis, ankylosing spondylitis, and psoriasis in China. These diseases not only affect patients' physical function and quality of life, but also impose a huge economic burden to their families due to the long-term drug use. Junshi is actively pursuing its commitment to 'provide better effective and economical treatment options for patients', and we believe that the approval of 君迈康? will bring new hope to the majority of patients with autoimmune diseases in China. We are looking forward to, with the efforts of our partner Mabwell in the future, more Chinese and global patients benefiting from this high-quality biological drug from China."